JP2022545647A5 - - Google Patents
Info
- Publication number
- JP2022545647A5 JP2022545647A5 JP2022509082A JP2022509082A JP2022545647A5 JP 2022545647 A5 JP2022545647 A5 JP 2022545647A5 JP 2022509082 A JP2022509082 A JP 2022509082A JP 2022509082 A JP2022509082 A JP 2022509082A JP 2022545647 A5 JP2022545647 A5 JP 2022545647A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- domain
- domains
- binding
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025015817A JP2025072461A (ja) | 2019-08-15 | 2025-02-03 | 細胞標的化のための多重特異性抗原結合分子およびそれらの使用 |
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962887411P | 2019-08-15 | 2019-08-15 | |
| US62/887,411 | 2019-08-15 | ||
| US201962924435P | 2019-10-22 | 2019-10-22 | |
| US62/924,435 | 2019-10-22 | ||
| US202062978584P | 2020-02-19 | 2020-02-19 | |
| US62/978,584 | 2020-02-19 | ||
| US202063057824P | 2020-07-28 | 2020-07-28 | |
| US63/057,824 | 2020-07-28 | ||
| PCT/US2020/046352 WO2021030680A1 (en) | 2019-08-15 | 2020-08-14 | Multispecific antigen-binding molecules for cell targeting and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025015817A Division JP2025072461A (ja) | 2019-08-15 | 2025-02-03 | 細胞標的化のための多重特異性抗原結合分子およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022545647A JP2022545647A (ja) | 2022-10-28 |
| JP2022545647A5 true JP2022545647A5 (enExample) | 2023-08-10 |
| JP7629906B2 JP7629906B2 (ja) | 2025-02-14 |
Family
ID=72243251
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022509082A Active JP7629906B2 (ja) | 2019-08-15 | 2020-08-14 | 細胞標的化のための多重特異性抗原結合分子およびそれらの使用 |
| JP2025015817A Pending JP2025072461A (ja) | 2019-08-15 | 2025-02-03 | 細胞標的化のための多重特異性抗原結合分子およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025015817A Pending JP2025072461A (ja) | 2019-08-15 | 2025-02-03 | 細胞標的化のための多重特異性抗原結合分子およびそれらの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US12077603B2 (enExample) |
| EP (1) | EP4013797A1 (enExample) |
| JP (2) | JP7629906B2 (enExample) |
| KR (1) | KR20220044821A (enExample) |
| CN (2) | CN114302893B (enExample) |
| AU (1) | AU2020330063A1 (enExample) |
| BR (1) | BR112022002012A2 (enExample) |
| CA (1) | CA3147791A1 (enExample) |
| IL (1) | IL290299A (enExample) |
| MX (1) | MX2022001942A (enExample) |
| TW (2) | TWI890689B (enExample) |
| WO (1) | WO2021030680A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016161010A2 (en) | 2015-03-30 | 2016-10-06 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| AU2016325630B2 (en) * | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| EP4004049A1 (en) | 2019-07-24 | 2022-06-01 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors with mage-a4 specificity and uses thereof |
| KR20230121854A (ko) | 2020-12-17 | 2023-08-21 | 리제너론 파아마슈티컬스, 인크. | 단백질-캡슐화 마이크로겔의 제작 |
| MX2023008527A (es) | 2021-01-20 | 2023-07-28 | Regeneron Pharma | Metodos para mejorar el valor proteico en cultivo celular. |
| AU2022271212A1 (en) * | 2021-05-04 | 2023-11-30 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors with mage-a4 specificity and uses thereof |
| CA3227537A1 (en) * | 2021-07-27 | 2023-02-02 | Morphosys Ag | Combinations of antigen binding molecules |
| WO2023183758A2 (en) * | 2022-03-19 | 2023-09-28 | Regeneron Pharmaceuticals, Inc. | Multispecific molecules targeting cd3 and mage-a4 and uses thereof |
| JP2025525886A (ja) * | 2022-08-02 | 2025-08-07 | オーエスイー・イミュノセラピューティクス | Ｃｄ２８に対する多機能性分子 |
| JP2026507123A (ja) * | 2023-02-28 | 2026-02-27 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | Ｔ細胞活性化剤およびその使用方法 |
| WO2025199278A2 (en) | 2024-03-20 | 2025-09-25 | Regeneron Pharmaceuticals, Inc. | Masked multispecific antigen-binding molecules with cleavable linkers |
| WO2025255480A1 (en) * | 2024-06-07 | 2025-12-11 | Regeneron Pharmaceuticals, Inc. | Tetravalent multispecific binding molecules and methods of use thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991003493A1 (en) * | 1989-08-29 | 1991-03-21 | The University Of Southampton | Bi-or trispecific (fab)3 or (fab)4 conjugates |
| US7550143B2 (en) * | 2005-04-06 | 2009-06-23 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| CA2604032C (en) * | 2005-04-06 | 2017-08-22 | Ibc Pharmaceuticals, Inc. | Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses |
| PE20120540A1 (es) * | 2009-05-27 | 2012-05-09 | Hoffmann La Roche | Anticuerpos triespecificos o tetraespecificos |
| MY192182A (en) | 2009-06-26 | 2022-08-04 | Regeneron Pharma | Readily isolated bispecific antibodies with native immunoglobulin format |
| SMT202600080T1 (it) | 2010-02-08 | 2026-03-09 | Regeneron Pharma | Topo con catena leggera comune |
| US20150203591A1 (en) * | 2012-08-02 | 2015-07-23 | Regeneron Pharmaceuticals, Inc. | Mutivalent antigen-binding proteins |
| JOP20200236A1 (ar) | 2012-09-21 | 2017-06-16 | Regeneron Pharma | الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها |
| JP2014124186A (ja) | 2012-12-26 | 2014-07-07 | Industrial Technology Research Institute | 多価抗体フラグメントおよびその三量体化複合体 |
| TWI635098B (zh) | 2013-02-01 | 2018-09-11 | 再生元醫藥公司 | 含嵌合恆定區之抗體 |
| WO2016105450A2 (en) * | 2014-12-22 | 2016-06-30 | Xencor, Inc. | Trispecific antibodies |
| WO2016161010A2 (en) | 2015-03-30 | 2016-10-06 | Regeneron Pharmaceuticals, Inc. | Heavy chain constant regions with reduced binding to fc gamma receptors |
| AU2016325630B2 (en) | 2015-09-23 | 2022-11-17 | Regeneron Pharmaceuticals, Inc. | Optimized anti-CD3 bispecific antibodies and uses thereof |
| WO2017106462A1 (en) * | 2015-12-18 | 2017-06-22 | Biogen Ma Inc. | Bispecific antibody platform |
| WO2017165464A1 (en) * | 2016-03-21 | 2017-09-28 | Elstar Therapeutics, Inc. | Multispecific and multifunctional molecules and uses thereof |
| WO2018014260A1 (en) * | 2016-07-20 | 2018-01-25 | Nanjing Legend Biotech Co., Ltd. | Multispecific antigen binding proteins and methods of use thereof |
| JP7066690B2 (ja) | 2016-09-23 | 2022-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 抗ｍｕｃ１６（ムチン１６）抗体 |
| WO2018178074A1 (en) * | 2017-03-29 | 2018-10-04 | F. Hoffmann-La Roche Ag | Trimeric antigen binding molecules specific for a costimulatory tnf receptor |
-
2020
- 2020-08-14 US US16/993,721 patent/US12077603B2/en active Active
- 2020-08-14 TW TW109127674A patent/TWI890689B/zh active
- 2020-08-14 TW TW114123254A patent/TW202542199A/zh unknown
- 2020-08-14 MX MX2022001942A patent/MX2022001942A/es unknown
- 2020-08-14 KR KR1020227008242A patent/KR20220044821A/ko active Pending
- 2020-08-14 JP JP2022509082A patent/JP7629906B2/ja active Active
- 2020-08-14 CN CN202080061412.XA patent/CN114302893B/zh active Active
- 2020-08-14 BR BR112022002012A patent/BR112022002012A2/pt unknown
- 2020-08-14 WO PCT/US2020/046352 patent/WO2021030680A1/en not_active Ceased
- 2020-08-14 EP EP20761991.7A patent/EP4013797A1/en active Pending
- 2020-08-14 CA CA3147791A patent/CA3147791A1/en active Pending
- 2020-08-14 CN CN202510048366.4A patent/CN119954933A/zh active Pending
- 2020-08-14 AU AU2020330063A patent/AU2020330063A1/en active Pending
-
2022
- 2022-02-02 IL IL290299A patent/IL290299A/en unknown
- 2022-04-08 US US17/716,830 patent/US12065508B2/en active Active
- 2022-10-17 US US17/967,418 patent/US11952430B2/en active Active
-
2024
- 2024-07-23 US US18/781,515 patent/US20240368312A1/en active Pending
-
2025
- 2025-02-03 JP JP2025015817A patent/JP2025072461A/ja active Pending